Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

Inclusion Criteria: * Male or female subjects who are 18\~70 years of age on the day of signing informed consent, * Have a diagnosis of RA meeting the 1987 ACR/EULAR criteria of RA and ACR functional class I-III, * Body mass index (BMI = weight/height squared (kg/m2)) within the range of 19 to 30, * Have agreed to not use any anti- rheumatic drug except for study drugs during the study period. Exclusion Criteria: * Current therapy with any disease modifying anti-rheumatic drug (DMARD), with the exception of Methotrexate (MTX), Leflunomide, sulfasalazine, antimalarials, gold preparations, penicillamine, which must have discontinued for a period of at least 7 t1/2s prior to dosing, * Previous RA treatment with DMARDs or drugs with strong immunosuppressive effect in 3 months prior to dosing (12 months for rituximab or other B cell depleting agents), * Previous therapy with NSAIDs or oral glucocorticoids in 2 weeks before dosing, * Any parenteral (intramuscular or intravenous injection) or intra-articular corticosteroids therapy in 4 weeks before dosing, * Previous treatment with interferons in 4 weeks before dosing.